Tuesday, September 19, 2023
News Health
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Trial Halted for Bleeding Reduction With Abelacimab in AF

September 19, 2023
in Health News
Share on FacebookShare on Twitter


A phase 2 trial of the investigational factor XI inhibitor, abelacimab, in patients with atrial fibrillation (AF) who are at moderate to high risk for stroke has been stopped early due to “an overwhelming reduction” in the primary endpoint — major and clinically relevant nonmajor bleeding — in patients taking abelacimab vs those on rivaroxaban.

The announcement of topline results of the AZALEA-TIMI 71 trial was made by Anthos Therapeutics, the company developing abelacimab.

“The AZALEA-TIMI 71 study is the largest and longest head-to-head study of a Factor XI inhibitor to provide definitive evidence of a highly significant reduction in bleeding as compared to the standard-of-care anticoagulant,” Marc Sabatine, MD, chair of cardiovascular medicine at Brigham and Women’s Hospital, and chair of the TIMI study group, stated in the Anthos press release.

“With a median of 21 months of follow-up, spanning more than 2,000 patient years, AZALEA-TIMI 71 represents a landmark study confirming the promise of Factor XI inhibition as causing substantially less bleeding than a current standard-of-care,” Sabatine added.

Abelacimab is a novel, highly selective, fully human monoclonal antibody with dual inhibitory activity against factor XI and its active form, factor XIa. At the 150-mg dose given subcutaneously once monthly, the drug maintains around 98% inhibition of factor XI, in line with the benign bleeding profile of patients with genetic factor XI deficiency, the company notes.

The AZALEA-TIMI 71 study is an event-driven, randomized study comparing two blinded doses of abelacimab (90 mg or 150 mg given by subcutaneous injection once-monthly) with rivaroxaban 20 mg daily in 1287 patients with AF who are at moderate to high risk for stroke. Full results of the study will be presented at an upcoming scientific congress.

Patients in the rivaroxaban arm can transition to abelacimab in an extension study.

In a previous proof-of-concept study published in The New England Journal of Medicine in 2021, a single IV dose of abelacimab achieved a large reduction in venous thromboembolism (VTE) vs enoxaparin in patients undergoing knee surgery.

A phase 3 trial in AF patients is now planned. The LILAC-TIMI 76 study is an event-driven, randomized trial to evaluate the efficacy and safety of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism in AF patients who have been deemed to be unsuitable for currently available anticoagulation therapy. Patients will be randomized to receive abelacimab 150 mg subcutaneously or matching placebo once monthly. The researchers aim to enroll approximately 1900 patients from North America, Europe, Latin America, the Middle East, and Asia.

Dan Bloomfield, MD, chief medical officer of Anthos Therapeutics, said that, “Abelacimab embodies its promise as a hemostasis-sparing anticoagulant and represents a paradigm shift in the prevention of stroke and other thrombotic conditions.”

It is estimated that 12.1 million people in the United States will have AF by 2030, but 40%-60% of patients with AF are not prescribed anticoagulants today, one of the main reasons being concerns about bleeding, the company notes.

“Abelacimab has the potential to provide a game-changing treatment option for all those patients who live with the daily fear of bleeding while taking current anticoagulants,” said Leslie Lake, president of the National Blood Clot Alliance, in a quote.

Abelacimab has been granted a fast-track designation by the US Food and Drug Administration for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Several other Factor XI inhibitors are in development and have also shown promising results in terms of a more benign bleeding profile than current standard-of-care anticoagulants.

For more news, follow Medscape on Facebook, X (formerly known as Twitter), Instagram, and YouTube





Source link : https://www.medscape.com/viewarticle/996587?src=rss

Author :

Publish date : 2023-09-19 16:27:00

Copyright for syndicated content belongs to the linked Source.
Previous Post

Therapeutic Vaccine Shows Promise in Treating Lung Cancer

Related Posts

Health News

Therapeutic Vaccine Shows Promise in Treating Lung Cancer

September 19, 2023
Health News

DeepMind AI can predict if DNA mutations are likely to be harmful

September 19, 2023
Health News

Paxlovid, Lagevrio Benefit COVID Outpatients in Omicron Era

September 19, 2023
Health News

Nicky Newman: Celebrities pay tribute to inspirational cancer campaigner

September 19, 2023
Health News

The Rise of Anti-Science Rhetoric Is a ‘Lethal Force’

September 19, 2023
Health News

Emerging Risk Factors for Cardiovascular Disease in Women

September 19, 2023
Load More

Trial Halted for Bleeding Reduction With Abelacimab in AF

September 19, 2023

Therapeutic Vaccine Shows Promise in Treating Lung Cancer

September 19, 2023

DeepMind AI can predict if DNA mutations are likely to be harmful

September 19, 2023

Paxlovid, Lagevrio Benefit COVID Outpatients in Omicron Era

September 19, 2023

Nicky Newman: Celebrities pay tribute to inspirational cancer campaigner

September 19, 2023

The Rise of Anti-Science Rhetoric Is a ‘Lethal Force’

September 19, 2023

Emerging Risk Factors for Cardiovascular Disease in Women

September 19, 2023

Real-World Semaglutide Weight Loss Below Trial Levels

September 19, 2023
Load More

Categories

Tags

curcumin (2) diet (2) Keto (2)

Archives

September 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
« Aug    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version

Trial Halted for Bleeding Reduction With Abelacimab in AF- https://www.matt-daly.com   https://www.instruments-demusique.com/   https://www.1001vins.info/   https://newshealth.biz   https://monmaillotdebain.com   https://www.news-in-europa.com   https://chaussuresx.fr   https://signaturecleaningtn.com   -/- GCHQ breached privacy rights of IT professional and security researcher, human rights court rules   Klischtschijiwka: Ukrainische Armee meldet Rückeroberung weiteren Dorfes nahe Bachmut   Mini Chitarra Da Collezione Replica in Legno-Black Label Society-Zakk Wylde [Import]   -*- Yes beats U Mobile’s 5G unlimited home broadband with better and cheaper subscription   ECB pledge to treble number of girls teams by 2026   */* Hen And Stag Accessories Lot De 4 Saxophones Gonflables   X24 BOUTEILLES Château Beaucastel « Hommage à Jacques Perrin » 2014 75 cl AOC Châteauneuf du Pape Vin Rouge   Bach au XXIe Siècle : Bach et ses Fils (+ 1 CD)   * A.J. Ellender football game postponed following severe weather on Thursday night   A Treblinka, les chambres à gaz du camp d’extermination sortent de terre   Trial Halted for Bleeding Reduction With Abelacimab in AF *Trial Halted for Bleeding Reduction With Abelacimab in AF

NEWSHEALTH : Trial Halted for Bleeding Reduction With Abelacimab in AF